Aktis Oncology(AKTS.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Aktis Oncology
AKTS.US
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer.
1.880 T
AKTS.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    The prices of some memory modules have surged over 300%, with reports indicating that the storage market has entered a super bull market

    Recently, the prices of memory modules have skyrocketed, with DDR5 memory modules increasing by over 300% since September 2025, and DDR4 memory modules rising by over 150%. Industry insiders point out that the price increase is due to a surge in storage demand triggered by AI, with AI servers requiring 8-10 times more memory than regular servers, consuming 53% of the global monthly memory production capacity. Global cloud service providers are issuing massive purchase orders, and the storage market has entered a "super bull market," surpassing the historical high point of 2018

    Wallstreetcn·
    US
    MU
    +7.76%
    US
    SNDK
    +1.07%
    Wallstreetcn·
    US
    MU
    +7.76%
    US
    SNDK
    +1.07%

    Aktis Oncology Files Initial Beneficial Ownership Statement Listing Eli Lilly as 10% Owner

    Aktis Oncology Inc. has filed an initial beneficial ownership statement, identifying Eli Lilly & Co. as a 10% owner. The filing is accessible through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice. The original content was published via EDGAR by Aktis Oncology Inc. on January 15, 2026.

    Reuters·
    US
    LLY
    +0.53%
    US
    AKTS
    -3.94%
    Reuters·
    US
    LLY
    +0.53%
    US
    AKTS
    -3.94%

    Insiders Make Bold Move as Key Players Double Down on Aktis Oncology

    Aktis Oncology, Inc. (AKTS) experienced significant insider buying on January 14, 2026, with major stakeholders showing confidence in the company's future. Notable transactions include Ansbert Gadicke acquiring 1,112,777 shares for $20,029,986 and Director Todd Foley purchasing 232,870 shares for $4,191,660. Additionally, MPM BIOVENTURES 2018, L.P. matched Gadicke's purchase, indicating strong insider support. Despite a year-to-date price performance of -4.69%, these moves reflect a bullish outlook from key players.

    Tip Ranks·
    US
    AKTS
    -3.94%
    Tip Ranks·
    US
    AKTS
    -3.94%

    10% Owner Ansbert Gadicke Reports Acquisition of Aktis Oncology Inc. Common Shares

    Ansbert Gadicke, a 10% owner, has reported the acquisition of common shares of Aktis Oncology Inc. (AKTS). The filing includes several reporting owners, such as MPM Asset Management LLC. The full filing is accessible via the provided link. This news brief was generated by Public Technologies (PUBT) and is for informational purposes only, not to be considered as financial, investment, or legal advice.

    Reuters·
    US
    AKTS
    -3.94%
    Reuters·
    US
    AKTS
    -3.94%

    Assessing Aktis Oncology (AKTS) Valuation After Recent Share Price Movement And Ongoing Losses

    Aktis Oncology (AKTS) has gained attention following a 3% daily share price movement, despite a year-to-date gain of 20.83% against a backdrop of significant losses. The company reported US$5.56 million in revenue and a US$60.649 million loss, leading to a Price-to-Book ratio of -8.6x, indicating negative equity. This unusual ratio suggests a need for careful evaluation of its capital structure and funding profile. Investors are encouraged to consider both the potential rewards and risks associated with Aktis Oncology's clinical and financial situation.

    Simplywall·
    US
    AKTS
    -3.94%
    Simplywall·
    US
    AKTS
    -3.94%
    © 2026 Longbridge｜Disclaimer